See All News >
As Market Froths, Blueprint Medicines (BPMC) Debuts $147 Million IPO for Massachusetts' Biggest Recent IPO
Amgen (AMGN)’s T-Vec Cancer Therapy Gets FDA Panel OK
Novo Nordisk A/S (NVO) CEO Candidate Abruptly Departs and Company Starts Hunt Afresh
Kythera (KYTH) Grabs FDA Approval for Chin Fat-Busting Drug
Bay Area MyoKardia Snags $46 Million in Series B Financing Amid Rumors of Future IPO
Mystery Fortune 500 Pharma Company Rumored to Be McKesson Corporation Buys Land in New York, Promises 164 New Jobs
Analyst Says FDA Panel Lukewarm on Amgen (AMGN) Cancer Drug, As Company Deals With Split Personality
THERAVECTYS Upped Hiring Almost Five-Fold in 2014, As Biotech Booms, Says HR Head
Outgoing Ariad (ARIA) CEO Has No Regrets and "Will Work Harder Than Ever" Until a Successor is Named
Is Cheese The Secret To A Longer Life And Faster Metabolism? Aarhus University Study
Mirna Therapeutics Rakes in $41.8 Million in Series D As Lonestar Bio Booms
Ariad (ARIA) CEO Leaves Amid Proxy Battle with Hedge Fund Sarissa, Inc.
Everything You Wanted to Know About Biosimilars But Were Afraid to Ask: An Expert Interview
Biogen (BIIB) CEO Rehashes Old ALS Clinical Trial
Northwestern Medicine Researchers Solve Mystery Of Deadly Transplant Infection
Despite Patent Battle Worth Billions, CRISPR Raises $64 Million in Series A & B Rounds
Celgene (CELG) Dealmaking Continues With Two Pacts Worth $110 Million With Agios (AGIO), Northern Biologics
EXCLUSIVE: Integrated DNA Technologies Will Hire Dozens Over Next Few Years As New Redwood City Site Grows
See All News >